High baseline plasma levels of TNF-alpha, IL-6, and vWF significantly predicted new-onset ischaemic stroke over a 3-year follow-up in patients with chronic non-valvular atrial fibrillation.
Cohort (n=373)
Do baseline plasma levels of inflammatory variables predict the occurrence of ischaemic stroke in patients with chronic non-valvular atrial fibrillation?
Baseline plasma levels of TNF-alpha, IL-6, and vWF are significant predictors of new-onset ischaemic stroke in patients with chronic non-valvular atrial fibrillation.
The aim of the present study was to determine the rates of stroke in patients with chronic NVAF (non-valvular atrial fibrillation), evaluating the relationship between plasma levels of inflammatory variables at admission and the occurrence of stroke during a 3-year follow-up. A total of 373 consecutive patients with chronic NVAF were enrolled. Blood samples were drawn within 72 h of admission, and we evaluated plasma levels of IL (interleukin)-1beta, TNF-alpha (tumour necrosis factor-alpha), IL-6, IL-10, E-selectin, P-selectin, ICAM-1 (intercellular adhesion molecule-1), VCAM-1 (vascular cell adhesion molecule-1) and vWF (von Willebrand Factor). Subsequent patient events (stroke at follow-up) were monitored over a 3 year period. By multivariate analysis, only age, hypertension and high levels of IL-6, TNF-alpha and vWF remained significant predictors of a higher risk of experiencing ischaemic stroke at follow-up. Moreover, plasma values of TNF-alpha, IL-6 and vWF had a significant area under the ROC (receiver operating characteristic) curve. In conclusion, baseline plasma levels of TNF-alpha, IL-6 and vWF are predictors of new-onset ischaemic stroke at follow-up in patients with chronic NVAF.
Pinto et al. (Tue,) conducted a cohort in chronic non-valvular atrial fibrillation (NVAF) (n=373). Baseline plasma levels of inflammatory variables was evaluated on Ischaemic stroke. High baseline plasma levels of TNF-alpha, IL-6, and vWF significantly predicted new-onset ischaemic stroke over a 3-year follow-up in patients with chronic non-valvular atrial fibrillation.